Back to mobile site
Get it on Google Play

Longeveron receives committee approval to complete stem cell trial

May 11, 2026 9:10 AM EDT Send to a Friend
Longeveron Inc. (NASDAQ: LGVN) announced that an independent Data Monitoring Committee has completed its final review of the company's Phase ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login